Objective: To investigate the efficacy, safety, and clinical benefit of prolonged-release trazodone (Trittico) in the treatment of major depressive disorder (MDD). Methods: In this study, 363 Chinese patients with MDD were randomized 1:1 to receive either prolonged-release trazodone (150-450 mg) or placebo treatment for 6 weeks. The primary efficacy measurement was the change of the 17-item Hamilton Depression Rating Scale (HAMD-17) total score from baseline to the end of the study. The secondary efficacy measurements were the response and remission rates, the Clinical Global Impression - Improvement of Illness (CGI-I) score at the end of the study, and the change of the HAMD-14 total score and quality of sleep [evaluated by the Pittsburgh Sleep Quality Index (PSQI) scale] during the study period. Results: The mean maximum daily dose was 273.11 mg for the trazodone group and 290.92 mg for the placebo group. At the end of the study, there was a significant difference between the two groups in the HAMD-17 change score (trazodone vs. placebo: -11.07 vs. -8.29, p < 0.001). Trazodone showed advantages at 1 week of treatment, and the effect lasted until the end of the study (week 6). The response and remission rates of the trazodone group were significantly higher than those in the placebo group (response rate: 59.6 vs. 37.2%, p < 0.001; remission rate: 35.5 vs. 22.2%, p = 0.005). The majority of the adverse reactions of trazodone were mild to moderate, and the most frequent adverse reactions (≥5%) were dizziness, dry mouth, somnolence, and nausea. Conclusions: Prolonged-release trazodone was more effective than placebo in MDD and was well tolerated. i 2014 S. Karger AG, Basel

Ferrari AJ, Charlson FJ, Norman RE, et al: Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 2013;10:e1001547.
Nierenberg AA, Ostacher MJ, Huffman JC, et al: A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. J Occup Environ Med 2008;50:428-436.
Cipriani A, Furukawa TA, Salanti G, et al: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-758.
Gumnick JF, Nemeroff CB: Problems with currently available antidepressants. J Clin Psychiatry 2010;61:5-15.
Bayer AJ, Pathy MS, Cameron A, et al: A comparative study of conventional and controlled-release formulations of trazodone in elderly depressed patients. Clin Neuropharmacol 1989;12:50-57.
Moon CA, Laws D, Stott PC, et al: Efficacy and tolerability of controlled-release trazodone in depression: a large multicentre study in general practice. Curr Med Res Opin 1990;12:160-168.
Kasper S, Olivieri L, Loreto G, et al: A comparative, randomised, doubled-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Curr Med Res Opin 2005;21:1139-1146.
Munizza C, Olivieri L, Di Loreto G, et al: A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Curr Med Res Opin 2006;22:1703-1713.
Sheehan DV, Croft HA, Gossen ER, et al: Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study. Psychiatry 2009;6:20-33.
Sheehan DV, Rozova A, Gossen ER, et al: The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder. Psychopharmacol Bull 2009;42:5-22.
Stahl SM: Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 2009;14:536-546.
Wichniak A, Wierzbicka A, Soba$ska A, et al: The effectiveness of treatment with trazodone in patients with primary insomnia without and with prior history of hypnotics use. Pol Merkur Lekarski 2007;23:41-46.
Kaynak H, Kaynak D, GFzRkirmizi E, et al: The effective of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med 2004;5:15-20.
Zavesicka L, Brunovsky M, Horacek J, et al: Trazodone improves the results of cognitive behaviour therapy of primary insomnia in non-depressed patients. Neuro Endocrinol Lett 2008;29:895-901.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.